Baxter International, Inc. Presents Interim Phase 1 Safety and Tolerability Data at American Society of Hematology Meeting for Its Investigational Treatment for von Willebrand Disease

ORLANDO, Fla.--(BUSINESS WIRE)--Recombinant von Willebrand factor (rVWF) may be safe and well tolerated in patients with type 3 and severe type 1 von Willebrand disease, according to interim data from a Phase 1 multicenter, international clinical study presented today at the 52nd Annual Meeting of the American Society of Hematology.1 The interim data from 22 patients in the 32-patient study also suggest rVWF has a pharmacokinetic profile that is comparable to plasma-derived von Willebrand factor (pdVWF),1 the current standard for treatment for patients with the disease. The condition is associated with prolonged bleeding times, and the resulting complications can, in some cases, be considered life-threatening.2